Lakefront Biotherapeutics NV (LKFT)
Technology · NasdaqGS · US
Fundamentals
Valuation and ratings
Lakefront Biotherapeutics NV trades at USD29.60. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
LKFT passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
The full research page for LKFT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.